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93 Introduction 
As a basis to understand the aim of the present study, a brief overview of the relevant aspects 
of inflammatory bowel disease (IBD) and colorectal cancer in IBD as well as important 
results of previous studies in the field will be given in this introduction. 
3.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of disorders that causes inflammation of the 
intestine and sometimes also in organs external to the gut. The main forms of IBD are 
Crohn`s disease and ulcerative colitis. A third form, indeterminate colitis, comprises IBD 
cases in which a distinction between UC and CD cannot be made with certainty. Crohn's 
disease can affect any part of the alimentary tract, from mouth to anus, while ulcerative colitis 
is restricted to the large intestine, including the rectum. Crohns`s disease may show a variable 
extent of disease, with a defined border between affected and unaffected segments (skip 
lesions). Ulcerative colitis shows continuous inflammation, involving either the rectum only 
(proctitis), the rectum and the sigmoid (distal colitis), the distal colon up to the splenic flexure 
(left sided colitis), up to the hepatic flexure (substantial colitis) or including the coecum 
(pancolitis). Microscopically, Crohn`s disease may affect the whole bowel wall, whereas 
ulcerative colitis is limited to the inner lining of the gut, the epithelium.  
The risk of developing IBD in Norway has been investigated in several prospective studies 
during the last two decades and has been found to be one of the highest in the world. The 
incidence of Crohns`s disease ranged from 5.3/105 in western Norway [1] to 5.8/105 in 
Northern as well as in South-Eastern Norway [2, 3]. The incidence of ulcerative colitis was 
14.8/105, 12.8/105, and 13.6/105, respectively [4-6]. Diagnosis is made by an endoscopic 
examination (colonoscopy) with biopsy. The etiology of IBD is complex, involving inherited 
susceptibility and environmental factors. Although not fully understood, the inflammation is 
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thought to result from inappropriate and ongoing activation of the mucosal immune system 
driven by the presence of normal gut microbes [7, 8].  
The inflammation affecting the bowel wall causes symptoms ranging from abdominal pain 
and diarrhea in mild disease to blood in stool and weight loss in more severe cases. Onset of 
disease appears typically in young age, and once diagnosed, it is prevalent for the rest of the 
life, and may be invalidating due to complications. Many patients may, however, experience 
attenuating symptoms throughout course of disease, mainly as a consequence of treatment. 
Inflammation may subside spontaneously, but usually either medical or surgical treatment is 
necessary to get the symptoms under control and to prevent relapses.
3.2 Colorectal cancer in inflammatory bowel disease 
Patients with inflammatory bowel disease are at increased risk of colorectal cancer (CRC) [9-
12]. Due to a higher incidence of ulcerative colitis compared to Crohn`s disease, the risk of 
cancer has become more apparent in ulcerative colitis, but has also been recognized in 
Crohn`s disease with colonic involvement [13]. The mechanisms that lead to the initiation of 
neoplasia and the subsequent progression to cancer (carcinogenesis) are not fully understood. 
Some of the important hypothesis will be summarized in the following section. Cohort and 
case-control studies have unraveled associations between clinical and histological variables 
and cancer in IBD [14]. These risk factors will also be presented.  
3.2.1 Carcinogenesis of CRC in IBD 
Our understanding of the carcinogenesis in IBD has evolved during the past decades by 
learning from extensive research in sporadic colorectal cancer, which shows a much higher 
incidence rate. Progression to malignancy in sporadic cancer is thought to follow an adenoma-
cancer sequence, where adenomas are visible precursor lesions of the cancer. Although there 
is a tendency to multiplicity among adenomas, most sporadic carcinomas appear as solitary 
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tumors and neoplastic changes are found only in one affected segment of the colon. One has 
observed that the genomic instability increases in line with growth of the adenomas, giving 
rise to a high risk of cancer in adenomas larger than 1 cm in diameter [15]. Genomic 
instability comprises chromosomal as well as microsatellite instability [16]. Chromosomal 
instability, as evidenced by gains and losses of chromosome arms, leads to the loss of 
function of key tumor suppressor genes, such as APC and p53. Microsatellite instability, 
detected by using PCR with a panel of microsatellite markers, involves loss of function of 
DNA base mismatch repair genes, resulting in DNA replication errors throughout the genome. 
Furthermore, epigenetic events, such as methylation, can contribute to altered gene expression 
in colon carcinogenesis. 
The development of CRC in IBD shows many similarities with sporadic cancer, but 
also remarkable differences. Among these are lower age compared with sporadic CRC. The 
mean age at diagnosis of CRC in IBD is approximately 48 years [17, 18] as opposed to 70 
years in sporadic CRC [19]. Similar to sporadic cancer, neoplastic progression in ulcerative 
colitis is thought to occur in a stepwise manner, but generally from flat mucosa and not from 
adenomas as for sporadic carcinomas. They are therefore considered to be more difficult to 
detect at endoscopy. The precursor lesions in CRC-IBD are defined by specific morphologic 
changes of the mucosal cells (dysplasia) and are being graded according to the severity of the 
changes: normal mucosa – indefinite for dysplasia – low and – high grade dysplasia – cancer 
[20]. Dysplasia is generally diagnosed in colorectal biopsies taken either randomly or directed 
by visible and suspicious lesions of the colon, in which dysplasia sometimes occurs - DALM 
(dysplasia associated lesion or mass). Neoplasia in IBD is often multifocal. Dysplasia is often 
present at several regions throughout the colon, and up to 27% percent of patients show two 
or three tumors simultaneously at the time of diagnosis [21, 22]. This phenomenon also 
relates to molecular changes related to neoplasia in IBD. Genomic instability is found both in 
12
biopsies presenting dysplasia or cancer, but also in tissue that appears to be normal, i.e. 
without histological changes. The widespread molecular changes over a wider field than what 
is recognizable from structural damage, the so called “field effect”, has been postulated to 
characterize a wider area of genomic instability in the colon in IBD with a risk of malignant 
transformation [23-26]. On the one hand, there is evidence for the field effect to be as large as 
involving the entire colon [27], on the other hand several studies have shown that a 
considerable number of patients with CRC-IBD present with dysplasia contiguous but not 
distant from the cancer [28-30]. The interpretation of these findings is challenging and it is 
still unclear whether there are subgroups of CRC in IBD that do not follow the usual pattern 
of malignancy in IBD and whether there are several underlying molecular pathways of 
malignancy in IBD, that might modulate the field effect.   
The theory of the field effect implies that the mechanisms that cause initiation and 
progression to malignancy in IBD probably are widely distributed throughout the colon, at 
least in a selection of IBD patients with neoplasia. To what extent this is connected to the 
distribution of inflammation is unclear. However, since inflammation is one of the main 
characteristics of IBD and typically involves large regions of the intestine, it has been 
proposed to play a central role in carcinogenesis related to IBD [31].  
Two models for the development of malignancy have come into focus. One favors the 
assumption that chronic inflammation leads to telomere shortening. Telomers consists of 
repetitive DNA at the ends of the chromosomes, which protects the chromosomes from 
destruction. It shortens naturally with age but also by inflammation. Short telomers allow 
chromosome-ends to fuse together subsequently leading to chromosomal breaks, hence to 
gains and losses of chromosome arms [32].  The other model focuses on the relationship 
between inflammation and the production of reactive oxygen. Longstanding inflammation 
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might lead to oxidative stress, resulting in loss of DNA mismatch repair function or loss of 
other gene function and thus to genetic instability [33, 34]. 
Other clinical-histological features of CRC in IBD are quite similar to sporadic 
adenocarcinoma of the colorectum, although some differences have been observed. Some 
tumors in IBD may be entirely microscopic, without any abnormality of the mucosa at 
macroscopic inspection of the specimen [35]. A higher percentage of cancers in IBD occur in 
strictured segments of the colon [36, 37]. There seems to be a higher prevalence of mucinous 
carcinomas in IBD and more often advanced grade of malignancy compared with sporadic 
carcinomas [17, 28, 38].  
3.2.2 Incidence and risk factors of CRC in ulcerative colitis 
A population based study conducted in Sweden and published in 1990 reported a standardized 
incidence ratio (SIR, ratio of observed to expected cases) of 5.7 (95%CI: 4.6-7.0) for 
ulcerative colitis associated CRC. The risk of cancer was related to the colonic extent of 
disease. For patients with ulcerative proctitis the SIR was 1.7 (95%CI: 0.8-3.2), for those with 
left-sided colitis, 2.8 (95%CI: 1.6-4.4) and for those with substantial or pancolitis, 14.8 
(95%CI: 11.4-18.9) [9]. The risk of cancer was also related to age at diagnosis of ulcerative
colitis. For each increase in age group at diagnosis (<15 years, 15-29 years, 30-39 years, 40-
49 years, 50-59 years and >60 years), the relative risk of CRC, adjusted for the extent of 
disease at diagnosis, decreased by about fifty percent (adjusted SIR 0.51; 95%CI: 0.46-0.56).
Duration of disease seems to be another risk factor. A meta-analysis of 116 studies estimated 
a cumulative risk for any ulcerative colitis patient, irrespective of disease extent, to be 2% at 
10 years, 8% at 20 years and 18% at 30 years of disease duration [11]. The overall prevalence 
of CRC in any patient with UC in this study was 3.7%, increasing to 5.4% for those with 
pancolitis [11]. In spite of the effect of duration of IBD on the risk of acquiring CRC, several 
patients were reported with development of CRC during the first decade after diagnosis of 
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IBD. Prior to the present study, systematically collected data addressing this problem had not 
been available. In the meantime, however, a study conducted in the Netherlands has been 
published, reporting as much as 22% of patients with IBD developing CRC before 8 years of 
disease in pancolitis or 15 years in left-sided colitis[39]. In that study no attempt was made to 
identify risk factors for early onset of CRC in IBD.
3.2.3 Incidence and risk factors of CRC in Crohn`s disease 
As outlined above, Crohns`s disease may effect any part of the intestine, including the upper 
and lower gastrointestinal tract. Cancer in the small intestine related to Crohn`s disease has 
been observed, but the risk of adenocarcinoma is highest in patients with colonic 
inflammation only [10, 40]. The SIR for patients with Crohn`s disease with involvement of 
the colon only was 5.6 (95%CI: 2.1-12.2) in the aforementioned Swedish cohort [10]. Patients 
in whom Crohn`s disease was diagnosed before the age of 30 with any colonic involvement 
had a SIR of 9.5 (95%CI: 3.1-23.2) compared to a SIR of 1.6 (95%CI: 0.6-3.3) in patients 
older than 30 at diagnosis. The risk of CRC in Crohn`s disease was confirmed by a meta-
analysis including 6 reports from the USA, Sweden, Denmark, Israel and Canada [12]. The 
pooled SIR for colon cancer in Crohn`s disease with colonic involvement was 2.5 (95%CI: 
1.7-3.5).
The risk of cancer in ulcerative colitis and Crohn`s disease was directly compared in a study 
published in 1994 and found to be similar [41]. In this cohort, consisting of patients from 
England and Sweden, the relative risk for developing CRC, adjusted for age, gender, and 
years of follow up, was 19.2 (95%CI: 12.9-27.6) in ulcerative colitis and 18.2 (95%CI: 7.8-
35.8) in Crohn`s disease. Although most cancers in Crohn`s disease have been found in 
segments of the colon with evidence of inflammation [42-44], in some cases the tumor has 
been diagnosed in regions of the intestine devoid of endoscopic or pathological signs of 
inflammation [36, 45-47]  
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3.2.4 Miscellaneous risk factors for CRC in IBD 
Other important risk factors for CRC in IBD are the occurrence of CRC in relatives of the 
IBD patients, the severity of the colonic inflammation and the diagnosis of primary sclerosing 
cholangitis, which is an inflammation of the bile ducts due to an autoimmune reaction.  
A population based cohort study of 19876 individuals with ulcerative colitis or Crohn`s 
disease, born between 1941 and 1955 examined the risk of CRC in IBD with and without a 
family history of CRC [48]. Patients who had a first degree relative with CRC had a relative 
risk of 2.0 (95%CI: 1.0-4.1) for the diagnosis of CRC compared to patients with no family 
history of CRC and the relative risk was higher for patients with a first degree relative who 
had been younger than the age of 50 at diagnosis of CRC. Interestingly, in that study, IBD 
patients with relatives who had also been diagnosed with IBD but not with CRC, had no 
increased risk of CRC compared to those IBD patients with no family history of IBD.  
An early study of the course and prognosis of ulcerative colitis reported a higher risk of 
cancer in IBD patients with chronic continuous symptoms compared to chronic intermittent 
symptoms [49]. On the other hand, two subsequent studies analyzing the relationship between 
the frequency of clinical exacerbations and the risk of CRC failed to show an association [50, 
51]. Recent publications, however, have given substantial support to the relationship between 
the severity of inflammation and the risk of cancer in IBD. A case control study from England 
in 2004 involved 68 cases and 136 matched controls and showed a correlation between 
neoplastic progression and an inflammation score that summarized the severity of 
inflammation in a single value covering the entire course of disease for each subject [52]. 
Adjusted for family history of CRC, medical treatment, smoking status, and concomitant 
primary sclerosing cholangitis, a 1-unit increase in this histological score increased the odds 
of CRC by a factor of 4.69 (95%CI: 2.10 -10.48, p<0.001). A subsequent cohort study from 
USA investigated the effect of changes in inflammation over time by using proportional 
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hazards analysis (Cox regression) of grade of histological inflammation coded as time 
changing covariate [53]. Of the 418 patients who all entered the colon cancer surveillance 
program without known dysplasia, 15 progressed to advanced neoplasia (five 
adenocarcinomas and ten high grade dysplasia) during follow-up. Adjusted for the frequency 
of endoscopy, a 1-unit increase in the histological inflammation score increased the risk of 
advanced neoplasia by a factor of 3.8 (95% CI: 1.7-8.6).
The risk of neoplasia in patients with IBD combined with PSC is controversial. Several 
studies have indicated that patients with IBD and PSC are at a higher risk of acquiring 
colorectal neoplasia [54-57], whereas larger studies from the Mayo clinic reported no risk 
[58] or only a borderline increased risk [59].
3.2.5 Protective factors for CRC in IBD 
In addition to decreased symptom activity and reduced severity of inflammation, treatment of 
IBD with medical compounds such as Sulfasalzine or Mesalamine (5-ASA compounds) may 
have a protective effect on the neoplastic progression in IBD [60]. In a study involving 18969 
patients with IBD in the UK General Practice Research Database, regular users of 5-ASA 0-
12 and 12-24 months prior to the diagnosis of CRC had a significantly reduced risk of CRC 
compared with irregular users [61]. This study also showed a different risk reduction of 
Sulfasalazine compared to Mesalamine. Because Sulfasalazine inhibits the absorption of 
Folate [62] and Folate deficiency is correlated to a higher risk of sporadic neoplasia [63], it is 
possible, that the lack of cancer prevention of Sulfasalazine may be a result of reduced folate 
absorption [64]. The chemoprotective effect of mesalamine seems to be dose-dependent. A 5-
ASA dose, equivalent to mesalamine of at least 1.2g/day provided the greatest risk reduction 
(72%-81%) [51, 65].
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An important confounder of cancer protective factors in IBD might be the frequency of 
consultations with a clinician. Visiting a hospital doctor more than twice a year reduces the 
risk of cancer by 84% (p=0.006) [51]. 
3.2.6 Prognosis of CRC in IBD 
Previous studies have shown conflicting results regarding the survival of CRC-IBD compared 
to CRC without IBD.  A cohort study conducted in Great Britain in 1984 [18] and two case-
control studies from the Mayo clinic, published in 1980 and 2006 reported similar survival in 
CRC-IBD compared to CRC without IBD [17, 66]. In contrast, two Danish studies in 
2006/2007 showed poorer survival in CRC-IBD compared to CRC without IBD [67, 68]. 
While the studies from Great Britain and from the Mayo clinic were hospital based, the 
Danish studies were population based, by recruitment of the patients in a nationwide database 
between 1977 and 1999. Compared to 71000 patients with non-IBD CRC, the mortality rate 
ratio, adjusted for age and other important covariates, were 1.24 after one year and 1.17 after 
five years of follow up for 279 patients with ulcerative colitis-CRC and 1.82 and 1.57, 
respectively, for 100 patients with Crohn`s disease-CRC [67, 68] 
3.2.7 The management of cancer risk in IBD 
The question which is the best strategy to manage cancer risk in patients with IBD is 
controversial. Over the past 30 years, colonoscopic surveillance for dysplasia every second 
year from 8-10 years disease duration has been advocated [69], instead of preventive removal 
of the colon [70]. This strategy is based on the association of dysplasia and cancer. A 
systematic review of 10 prospective studies reported in 1994 that 42% of patients with high-
grade dysplasia and 19% of patients with low-grade dysplasia had synchronous cancers at the 
time of the surgical removal of the colon (colectomy) [71], and that 16-29% of patients with 
untreated low-grade dysplasia progressed to DALM, high grade dysplasia or cancer. On the 
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other hand, screening for dysplasia has shown to face serious difficulties. As mentioned 
before, dysplasia is not visible by inspection and occurs in patches. It takes 33 or more 
random biopsies to have 90% confidence of finding dysplasia [70, 72]. Also the histological 
evaluation of the biopsies encounters uncertainty. There is a considerable variability in the 
diagnosis of low or high-grade dysplasia among pathologists (inter-observer variability) and 
also on a second reading of the same slide by the same pathologist (intra-observer variability) 
[20, 73, 74]. The subgroup of patients who develop cancer within eight years disease duration, 
that is, before guidelines recommend inclusion in surveillance programs might be erroneously 
excluded from surveillance [75]. This adds to the confusion regarding the recommendation of 
surveillance programs. A Cochrane review revealed recently, that there is no conclusive 
evidence that surveillance colonoscopy prolongs survival in patients with extensive colitis 
[70, 76].
3.3 Summary of introduction 
In summary, patients with ulcerative colitis and with Crohn`s disease with colonic 
involvement are at increased risk of developing colorectal cancer. Risk factors include young 
age at onset of IBD, extensive disease and long disease duration, severity of inflammation, 
diagnosis of primary sclerosing cholangitis and genetic susceptibility. Some patients develop 
cancer early during the course of disease. The magnitude of this phenomenon is not yet 
thoroughly investigated and risk factors for early CRC in IBD have not been identified so far. 
Therapy with a 5-ASA compound probably reduces the risk of cancer. Compared to CRC in 
the general population, the prognosis of CRC in IBD is poor. Cancer screening strategies have 
not shown the desired efficacy in the prevention and early detection of cancer in IBD. 
More knowledge about factors that influence carcinogenesis in IBD is needed, especially with 
regard to the possibility, that the etiology of CRC in IBD might be more heterogeneous than 
previously believed. In addition to patients with IBD and concomitant primary sclerosing 
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cholangitis, possible subgroups with increased risk of CRC in IBD have not been identified. It 
is also possible that disease behavior and risk factors are different between countries, which 
stress the importance of population based studies. 
4 Aims of the study 
1. To determine the variability of the colitis-CRC interval and to identify risk factors for 
early onset of CRC in IBD in a Norwegian population based cohort. 
2. To identify new subgroups of CRC in IBD by analyzing the histological variability of 
CRC in IBD and possible associations with clinical parameters. 
3. To analyze the effect of clinical and histological factors on the prognosis of CRC in IBD. 
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6 Methodological considerations 
6.1 Recruitment of the patients with CRC-IBD  
All patients who had been electronically recorded with the diagnosis of Crohn`s disease 
(International Statistical Classification of Disease and Related Health Problems 9th revision 
(ICD-9); 555 and 10th revision (ICD-10); K50), or with ulcerative colitis (ICD-9: 556, ICD-
10: K51) or non-infectious colitis (ICD-9: 153, ICD-10: K52) at Rikshospitalet University 
Hospital in the period 28.02.1973 – 30.04.2005 (n=3285), at Akershus University Hospital in 
the period 12.12.1985-09.02.2004 (n=4795) as well as patients from the prospectively 
recorded IBD cohort from Aker University Hospital (1987-2004, n=1010) were matched 
against the CRC files (ICD-9: 153, ICD-10: C18) at the Cancer Registry of Norway.
Thus, out of 9090 patients with a possible diagnosis of IBD, 370 patients with the diagnosis of 
cancer in the colorectum were identified. Five patients who had been diagnosed with CRC in 
IBD at Rikshospitalet University Hospital prior to 1973 were also included.
By review of clinical data and histological re-analysis of the biological material, 289 patients 
were confirmed of having CRC but showed no evidence of IBD. The majority of these 
patients had been diagnosed with diarrhea secondary to adjuvant therapy of sporadic cancer 
and had thus been coded with the “non-infectious colitis” ICD-codes. Of the remaining 81 
tentative study cases, several patients had to be excluded: One patient refused participation in 
the study, in three patients biopsies for re-analysis were no longer available, one patient had 
carcinoid cancer in IBD, one neuroendocrine differentiated carcinoma in IBD and one 
squamous cell carcinoma of the anus, six patients were diagnosed with adenocarcinoma in the 
colorectum prior to the diagnosis of IBD and one patient was completely lacking any clinical 
follow-up data. (figure1). Consequently, 67 patients with the diagnosis of adenocarcinoma in  
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the colorectum (CRC) in either ulcerative colitis (UC) or Crohn`s disease (CD) were included 
in the cohort. There were no patients with indeterminate colitis and CRC. 
6.2 Data collection 
Patient demographics, endoscopic findings, pathology reports and clinical data regarding the 
course of disease and treatment were reviewed and paraffin-embedded material from 
colectomy or endoscopy was re-analyzed. In case of incomplete files at the recruiting 
hospitals, patient journals were traced throughout health institutions in Norway and biopsies 
were collected from other hospitals when necessary. When original histological slides were 
not available, new slides were cut from the existing paraffin-blocks. All slides were evaluated 
by one experienced pathologist in a blinded fashion. When the re-evaluation deviated from 
the original pathology report, a consensus was achieved by consulting a third experienced 
pathologist.
6.3 Statistics 
Statistical analyses were performed by using SPSS 14.0. Groups were compared by using 
independent T-tests or one-way ANOVA for continuous outcome variables and Pearson Chi-
Square or Fisher`s Exact test for categorical outcome variables. Bonferroni correction was 
used for comparisons of groups with more than two categories. A dependent variable was 
explained by a set of independent factors by using linear regression analysis. Significant 
(p<0.05) and close to statistical significant factors (p<0.1) were stepwise included into a 
multiple linear regression model. In multiple logistic regression analysis, forward variable 
selection procedure was used to find the model that best predicted the factor of interest. For 
survival analysis, Cox regression was used to compute hazard ratios for death (mortality rate 
ratio) in CRC-IBD compared to all CRC in the general population, adjusting for cofactors.
24
6.4 Ethics 
The study protocol was approved by the Regional Committee for Medical and Health 
Research Ethics. Personal data was handled according to the license of the Data Inspectorate.
Patients were requested for written informed consent. In case of a deceased patient data were 
extracted by the permission of the Department of Health and Social Affairs.  
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7 Summary of the results 
7.1 Paper I 
Relationship between clinical parameters and the colitis-colorectal cancer interval in a 
cohort of patients with colorectal cancer in inflammatory bowel disease 
The study investigated the variability of the colitis-CRC interval and possible clinical risk 
factors for early onset of CRC in IBD. 
The median time from diagnosis of IBD to CRC was 17 years. Twelve percent of the patients 
developed CRC within 10 years from onset of IBD symptoms and 21% within 10 years after 
the diagnosis being confirmed. High age at onset of IBD symptoms and a high percentage of 
the colitis-CRC interval with active symptoms was associated to the development of CRC 
early in the course of IBD. High age at onset of IBD was also associated with advanced stage 
of cancer at diagnosis of CRC. Patients with PSC were significantly younger at onset of IBD 
symptoms, but the colitis-CRC interval was similar to IBD without PSC. Other potential 
clinical risk factors, such as the family history of CRC or IBD, and drug treatment, were not 
associated to the duration of the colitis-CRC interval. 
In summary, 21 % of the patients in the cohort developed cancer before screening with 
colonoscopy usually is recommended. High age at onset of IBD seems to be related to early 
CRC in IBD.
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7.2 Paper II 
Two distinct groups of colorectal cancer in inflammatory bowel disease 
The study investigated the histological variability of CRC in IBD and associations with 
clinical parameters. 
Seventy-seven adenocarcinomas were diagnosed among the 67 patients. Fifty-nine patients 
(88%) had one - and eight patients (12%) had multiple cancers in the colorectum. Dysplasia 
was found distant to the tumor in 43 of 60 (75%) patients. In 17 patients (25%), dysplasia was 
only presented contiguous to the cancer.  
The presence of multiple cancers or distant dysplasia in the colorectum (widespread neoplasia 
in IBD) was associated to young age at onset of IBD, a long duration of the colitis-CRC 
interval and the presence of active inflammation at time of the cancer diagnosis. Patients with 
no evidence of neoplasia apart from the tumor (localized Neoplasia in IBD) showed a higher 
age at onset of IBD and a wide variation of the colitis-CRC interval. However, the average 
duration of time from onset of IBD to diagnosis of CRC was significantly shorter compared to 
patients with widespread neoplasia in IBD. In fact, all patients diagnosed with cancer within 
ten years from onset of symptoms had localized neoplasia in IBD. By multiple logistic 
regression analysis, age at onset of IBD symptoms was the strongest predictor for distant 
dysplasia at time of cancer diagnosis.  
In summary, widespread and multifocal neoplasia occurs in the majority of cases with CRC in 
IBD and is associated to early onset of IBD. However, localized neoplasia may occur in about 
a quarter of the patients and shows an association to late onset of IBD. The two groups may 
represent different pathogenetic entities of neoplasia in IBD. 
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7.3 Paper III 
Widespread but not localized neoplasia in inflammatory bowel disease worsens the 
prognosis of colorectal cancer 
In this study we compared survival of CRC in IBD with CRC in the general population (all-
CRC), adjusting for possible general confounders and strictly IBD related cofactors including 
new variables, such as type of CRC in IBD.
Adjusted for cofactors, prognosis of CRC-IBD was poorer compared to all-CRC (mortality 
rate ratio (MRR) 3.71, 95%CI: 2.54-5.42, p<0.001). Prognosis of widespread neoplasia-IBD 
was poorer compared to all-CRC (MRR 4.27, 95%CI: 2.83-6.44, p<0.001) and compared to 
localized neoplasia-IBD (MRR 3.58, 95%CI: 0.87-14.72, p=0.076). Survival was not 
significantly different between localized neoplasia-IBD and all-CRC (p=0.132). The mean 
age at CRC diagnosis was 43 years in widespread, 52 years in localized neoplasia-IBD, and 
70 years in all-CRC. Patients with CRC-IBD younger than 45 years at cancer diagnosis had a 
shorter survival than those above 45 years; mortality rate ratio 3.9 (95%CI: 2.2-6.9) versus 3.2 
(95%CI: 1.9-5.5), respectively. 
In summary, CRC in IBD showed poorer prognosis compared to all-CRC. The unfavorable 
effect of IBD on survival after diagnosis of CRC was more pronounced in patients below 45 
years of age and in patients with widespread neoplasia in IBD. Low age at diagnosis may be a 
confounder for widespread neoplasia in IBD. The diagnosis of the topographical distribution 
of dysplasia seems to be an important prognostic factor in patients with CRC in IBD. 
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8 Discussion 
In this retrospective analysis we investigated colorectal cancer in IBD in Norway. The aim 
was to gain more knowledge about factors that influence carcinogenesis in IBD, especially 
with regard to the possibility that the etiology of CRC in IBD might be far more 
heterogeneous than so far understood. In the following section, the main results of our 
investigations will be reviewed in the context of the findings of other relevant studies and the 
possible contribution of our results to the understanding of CRC in IBD will be discussed.  
8.1 The colitis-CRC interval 
Twelve percent of the patients developed CRC within 10 years from onset of IBD symptoms 
and 21% within 10 years of having the diagnosis confirmed. International guidelines suggest 
to start surveillance in IBD after 8-10 years from onset of disease in patients with pancolitis 
and after 15 years in left sided-colitis [69, 77]. Hence, 21% of the patients with CRC in IBD 
in our cohort were diagnosed with malignancy before the start of surveillance usually is 
recommended. Similar figures have been reported by colleagues from the Netherlands 
investigating 149 patients, diagnosed with CRC in IBD between 1990 and 2006 [39]. There 
seems to be a high frequency of early CRC in IBD and it appears to be a worthwhile attempt 
to identify factors associated with this phenotype. 
We found an inverse relationship between age at onset of IBD and the duration of the colitis-
CRC interval. This association is known from two previous reports but has been criticized of 
being secondary to a selection bias, taking into consideration, that older people are at higher 
risk of dying before CRC in IBD may have developed [78],[79]. In contrast to this 
interpretation, we found a higher frequency of advanced cancer stages in late onset IBD, 
indicating the possibility of a more aggressive type of carcinogenesis in these patients. To our 
knowledge, we were the first to investigate specifically the effect of other clinical variables 
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and the duration of the colitis-CRC interval, but found no predictors of early CRC in IBD, 
except the duration of active symptoms measured as percentage of the colitis-CRC interval. 
Interestingly, medical treatment, which is advocated as being protective for CRC in IBD, did 
not show a prolonged duration of disease until cancer, and vice versa, primary sclerosing 
cholangitis, which is presumed to be a aggressive risk factor for CRC in IBD, did not show an 
association to the development of cancer early during course of disease. Clinical factors alone 
could not sufficiently explain early CRC in IBD and it seemed reasonable to continue the 
search for new factors by analyzing histological characteristics in the cohort. 
8.2 Two groups of CRC in IBD 
A total of 915 paraffin blocks from 67 patients with CRC in IBD were reviewed. We found 
widespread, multifocal neoplasia in the majority, but localized neoplasia in about a quarter of 
the patients. These results can in part be interpreted in the light of earlier studies. Dysplasia 
being absent apart from the tumor in 25% of CRC-IBD has been recognized previously in 
several studies [28-30]. These studies were conducted when dysplasia as a marker for 
malignancy was relatively new and its predictive value for concurrent cancer the focus of 
investigation. The interpretation of the results addressed the question whether dysplasia was a 
predictive factor for cancer in IBD or not, and did not include the concept of different 
extension of dysplasia representing specific entities of CRC in IBD. As summarized by 
Ransohoff et al [30]: “The results suggest that failure to detect dysplasia may not exclude the 
presence of concurrent carcinoma”. The association between clinical factors and the 
topographical distribution of dysplasia was not analyzed in their studies. 
In our cohort, widespread neoplasia in IBD was related to young age at onset and long 
duration of disease, and furthermore, to active inflammation at time of cancer diagnosis. Thus, 
this type of CRC in IBD seems to follow the traditional model of malignant development in 
IBD. Carcinogenesis in these patients appears to be initiated at young age and promoted 
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during a considerable time of disease in a wide field of the colon, possibly by IBD related 
factors, as for example inflammation. This would explain an increasing risk of cancer with 
duration of IBD and why this group rarely if ever develops malignancy within the first eight 
to ten years of disease.
We found localized neoplasia in IBD in about a quarter of the patients. These patients appear 
not to follow the traditional risk pattern of malignancy in IBD, as they showed late onset of 
IBD and in median, a relatively short colitis-CRC interval, including all patients with a 
diagnosis of CRC before the start of surveillance usually is recommended. We speculate that 
in localized neoplasia in IBD, initiation of the cancer may take place unrelated to IBD and 
that malignant changes, similar to sporadic CRC, accumulate over time in a small field of the 
colon before the onset of IBD. With onset of disease, IBD related immunogenic factors may 
accelerate the age related carcinogenesis in these patients, resulting in dysplasia and 
subsequently cancer at a single location before long-standing inflammation or other IBD 
related factors may give rise to neoplasia in a large field of the colon. Consequently, patients 
with advanced malignant changes prior to onset of IBD may progress to cancer within a 
shorter time than patients with an earlier stage of carcinogenesis at onset of disease. This 
model would explain the relatively wide variability of the colitis-CRC interval in patients 
with localized neoplasia in IBD and the fact that some are being diagnosed with CRC shortly 
after onset of IBD, or even before the onset of IBD symptoms, as shown in several cohorts, 
including our own.
8.3 Survival 
Compared to CRC in the general population, we found poorer survival of CRC in IBD, thus 
confirming the results of a Danish cohort [67, 68]. The fact that the Danish and our cohort 
were population based, might be the reason for the diverging results compared to earlier case-
control studies [17, 66]. Earlier studies have also been limited by the fact that IBD related 
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factors were lacking in the survival analysis. In the present study, we were able to include 
several new and relevant cofactors.
Young age at diagnosis of CRC and widespread neoplasia in IBD seemed to be related to poor 
prognosis in our cohort. We concluded, that age at diagnosis of CRC in IBD may be a 
confounder for the extension of neoplasia in the colon and suggest, that widespread neoplasia 
in the colon explains the poor prognosis of patients with CRC in IBD. Localized neoplasia in 
IBD showed no statistically significant difference in survival probabilities compared to all 
CRC in Norway. This might support the hypothesis that localized neoplasia in IBD might be 
related to sporadic CRC in the population. Other important cofactors, including IBD specific 
variables, as for example medical treatment, the number of colonoscopies during course of 
disease or the diagnosis of primary sclerosing cholangitis, seemed not to modulate prognosis 
in our cohort.
The diagnosis of the topographical distribution of dysplasia in the colon seems to be 
important for the assessment of prognosis in patients with CRC in IBD.  
8.4 Limitations and strength of the study 
The strength of our study was the use of the nationwide Cancer Registry of Norway as well as 
the thorough diagnostic work-up of the patients with CRC in IBD. Thus, we were able to 
reduce the selection bias to a minimum and include new factors relevant for IBD into 
analysis. A limitation of the study may be the lack of information about the causes of death. 
Whether death was directly related to CRC, for example to complications after surgery or to 
other factors, remains unknown. Another weakness of the study may be the limited number of 
patients with CRC in IBD, in spite of the fact that the size of our cohort is large compared to 
other studies. The close to normal distribution of the factor “duration of the colitis-CRC 
interval” may indicate a high representativity of the cohort. However, we were not able to 
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differentiate type of IBD in the analyses, i.e. ulcerative colitis versus Crohn`s disease, because 
the number of cases were too small.  
8.5 Conclusions 
In this retrospective analysis, we investigated the variability of clinical and histological 
factors in a population based Norwegian cohort of CRC in IBD. We also analyzed survival 
probabilities adjusted for cofactors which have so far not been subject of investigation in such 
patients. The main results of the studies can be summarized chronologically as follows: 
 Twelve percent of the patients experienced CRC in less than 10 years after the onset of 
IBD symptoms and 21% within 10 years after having the diagnosis confirmed.  
 High age at onset of IBD symptoms was associated to the development of CRC early 
during course of disease. 
 In 75% of the patients, we found multiple cancers and/or dysplasia distant to the tumor 
(widespread neoplasia in IBD). It was associated with young age at onset of IBD, a 
relatively long colitis-CRC interval and active inflammation at cancer diagnosis. In 25% 
of the patients, neoplasia was only presented contiguous to the tumor (localized neoplasia 
in IBD). It was associated with a relatively high age at onset of IBD and a short colitis-
CRC interval, including all patients who were diagnosed with cancer within 10 years from 
onset of symptoms. 
 Compared to all CRC in the background population, young age at diagnosis of CRC in 
IBD and widespread neoplasia in IBD showed poor prognosis. 
Based on the present results, not only the diagnosis of dysplasia but also the topographical 
distribution of dysplasia in the colon may be important to recognize during surveillance of 
IBD. Therefore, a high number of random biopsies and techniques with improved diagnostic 
yield, as chromoendoscopy, may be considered for cancer screening. One should also be 
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aware of the possibility, that patients with late onset of IBD may develop malignancy, 
unrelated to disease duration. By use of a combination of histological, clinical and 
demographic risk factors, one may reach at an early estimation of prognosis and relevant time 
of surgery, and as a consequence, a prolonged survival, in these patients. Future studies will 
improve our understanding of the disease mechanisms behind the divergent subgroups of 
patients with CRC in IBD. 
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